Table 1.
Patient characteristics and 10-year OS probabilities
| Erasmus MC (%) |
MSKCC (%) |
Total (%) |
Median OS | 10-year OS | |||||
|---|---|---|---|---|---|---|---|---|---|
| Months | 95% CI | P-value | % | 95% CI | |||||
| Total number of patients | 1048 (25) | 3064 (75) | 4112 | ||||||
| PATIENT CHARACTERISTICS | |||||||||
| Age | Median (IQR) | 64 (58–71) | 60 (50–68) | 61 (52–69) | <0.001 | ||||
| =<60 years | 349 (33) | 1594 (52) | 1943 (47) | 65 | 60–69 | 35 | 33–38 | ||
| >60 years | 699 (67) | 1470 (48) | 2169 (53) | 56 | 53–59 | 26 | 24–29 | ||
| Gender | 0.19 | ||||||||
| Female | 367 (35) | 1323 (43) | 1690 (41) | 58 | 54–63 | 33 | 29–35 | ||
| Male | 681 (65) | 1741 (57) | 2422 (59) | 60 | 57–65 | 29 | 27–31 | ||
| Year of surgery | <0.001 | ||||||||
| <2000 | 0 | 746 (24) | 746 (18) | 47 | 42–51 | 25 | 22–29 | ||
| ≥2000 | 1048 (100) | 2318 (76) | 3366 (82) | 63 | 60–67 | 32 | 30–34 | ||
| DISEASE CHARACTERISTICS | |||||||||
| Location CRC | <0.001 | ||||||||
| Right-sided | 192 (19) | 836 (28) | 1028 (26) | 49 | 47–54 | 27 | 24–31 | ||
| Left-sided | 454 (44) | 1402 (47) | 1856 (47) | 65 | 61–70 | 33 | 30–35 | ||
| Rectum | 379 (37) | 725 (25) | 1104 (28) | 58 | 55–64 | 29 | 26–33 | ||
| Missing | 23 | 101 | 124 | ||||||
| pT-stage | 0.002 | ||||||||
| 0 * | 26 (3) | 13 (1) | 39 (1) | 94 | 63-NR | 37 | 19–69 | ||
| 1 | 14 (1) | 85 (3) | 99 (3) | 105 | 59–155 | 47 | 36–61 | ||
| 2 | 146 (14) | 287 (10) | 433 (11) | 66 | 58–74 | 35 | 31–41 | ||
| 3 | 731 (71) | 1984 (72) | 2715 (72) | 58 | 56–63 | 30 | 28–32 | ||
| 4 | 113 (11) | 398 (14) | 511 (13) | 50 | 42–58 | 26 | 21–32 | ||
| Missing | 18 | 297 | 315 | ||||||
| pT-stage | 0.003 | ||||||||
| T 0–2 | 186 (18) | 385 (14) | 571 (15) | 67 | 63–82 | 37 | 33–42 | ||
| T 3–4 | 844 (82) | 2382 (86) | 3226 (85) | 57 | 55–61 | 30 | 28–32 | ||
| Missing | 18 | 297 | 315 | ||||||
| Nodal status CRC | <0.001 | ||||||||
| N0 | 421 (41) | 1126 (37) | 1547 (39) | 75 | 71–82 | 39 | 36–42 | ||
| N1 | 392 (38) | 1168 (39) | 1560 (38) | 55 | 52–59 | 26 | 24–29 | ||
| N2 | 211 (21) | 736 (24) | 947 (23) | 47 | 43–50 | 23 | 20–26 | ||
| Missing | 22 | 43 | 65 | ||||||
| Nodal status CRC | <0.001 | ||||||||
| N0 | 420 (41) | 1127 (37) | 1547 (38) | 75 | 71–82 | 39 | 36–42 | ||
| N+ | 609 (59) | 1906 (63) | 2515 (62) | 52 | 50–55 | 25 | 23–27 | ||
| Missing | 19 | 31 | 50 | ||||||
| Extrahepatic disease ** | <0.001 | ||||||||
| No | 940 (90) | 2704 (88) | 3644 (89) | 63 | 60–67 | 32 | 31–34 | ||
| Yes | 108 (10) | 360 (12) | 468 (11) | 40 | 37–45 | 14 | 11–19 | ||
| Disease-free interval | 0.24 | ||||||||
| ≤ 12 months | 734 (70) | 2085 (68) | 2819 (69) | 57 | 55–60 | 30 | 28–32 | ||
| > 12 months | 314 (30) | 973 (32) | 1287 (31) | 64 | 59–70 | 31 | 28–34 | ||
| Missing | 0 | 6 | 6 | ||||||
| Number CRLM | <0.001 | ||||||||
| 1 | 452 (44) | 1252 (41) | 1704 (42) | 71 | 66–76 | 35 | 32–38 | ||
| 2 | 211 (20) | 598 (20) | 809 (20) | 60 | 55–68 | 32 | 29–36 | ||
| 3 | 118 (11) | 391 (13) | 509 (13) | 55 | 49–58 | 29 | 24–34 | ||
| 4 | 89 (9) | 233 (8) | 322 (8) | 51 | 46–58 | 28 | 22–34 | ||
| 5–9 | 139 (13) | 451 (15) | 590 (15) | 47 | 42–52 | 23 | 19–28 | ||
| ≥10 | 29 (3) | 115 (4) | 144 (4) | 38 | 34–48 | 14 | 8–26 | ||
| 10 | 24 | 34 | |||||||
| Size largest tumor | <0.001 | ||||||||
| ≤ 5cm | 823 (83) | 2285 (76) | 3108 (78) | 65 | 62–68 | 33 | 31–36 | ||
| > 5cm | 163 (17) | 729 (24) | 892 (22) | 43 | 39–48 | 22 | 19–26 | ||
| Missing | 62 | 50 | 112 | ||||||
| Preoperative CEA | <0.001 | ||||||||
| ≤ 200 μg/L | 899 (92) | 2497 (91) | 3396 (92) | 61 | 58–65 | 32 | 30–34 | ||
| > 200 μg/L | 80 (8) | 234 (9) | 314 (8) | 48 | 41–51 | 19 | 14–25 | ||
| Missing | 69 | 333 | 402 | ||||||
| Resection margin involved | <0.001 | ||||||||
| No | 844 (85) | 2686 (89) | 3530 (88) | 63 | 59–66 | 32 | 30–34 | ||
| Yes | 155 (15) | 335 (11) | 490 (12) | 42 | 37–46 | 17 | 13–21 | ||
| Missing | 49 | 43 | 92 | ||||||
|
KRAS mutational status
|
<0.001 | ||||||||
| Wildtype | 131 (61) | 797 (59) | 928 (59) | 78 | 72–86 | 34 | 30–39 | ||
| Mutated | 85 (39) | 554 (41) | 639 (41) | 53 | 49–58 | 27 | 22–32 | ||
| Missing | 832 | 1713 | 2545 | ||||||
| BRAF mutational status | <0.001 | ||||||||
| Wildtype | 183 (97) | 1120 (96) | 1303 (96) | 72 | 66–79 | 33 | 29–37 | ||
| Mutated | 6 (3) | 49 (4) | 55 (4) | 40 | 35–70 | 22 | 11–46 | ||
| Missing | 859 | 1895 | 2754 | ||||||
| Histopathological growth pattern | <0.001 | ||||||||
| dHGP | 216 (24) | 254 (21) | 470 (22) | 86 | 75–104 | 41 | 36–48 | ||
| non-dHGP | 696 (76) | 970 (79) | 1666 (78) | 57 | 51–59 | 26 | 23–29 | ||
| Missing | 136 | 1840 | 1976 | ||||||
| TREATMENT CHARACTERISTICS | |||||||||
| Perioperative systemic CTx | <0.001 | ||||||||
| No CTx | 546 (53) | 241 (9) | 787 (21) | 53 | 48–60 | 26 | 22–30 | ||
| 5-FU only | 25 (2) | 549 (20) | 574 (15) | 53 | 50–59 | 28 | 24–32 | ||
| OXA- or IRINO | 461 (45) | 2007 (71) | 2468 (64) | 64 | 60–68 | 34 | 32–36 | ||
| Missing | 16 | 267 | 283 | ||||||
| Perioperative HAIP CTx | <0.001 | ||||||||
| No | 1037 (99) | 2014 (66) | 3051 (74) | 55 | 53–58 | 27 | 25–29 | ||
| Yes | 11 (1) | 1050 (34) | 1061 (26) | 73 | 68–83 | 40 | 36–43 | ||
Abbreviations: CEA: carcinoembryonic antigen, CI: confidence interval, CRC: colorectal cancer, CRLM: colorectal liver metastases, CTx: chemotherapy, HAIP: hepatic arterial infusion pump chemotherapy, HGP: histopathological growth pattern. IRINO: irinotecan, IQR: interquartile range, OXA: oxaliplatin, NR: not reached, pT-stage: pathology tumor stage
*
Rectal cancer with complete response after neoadjuvant chemoradiotherapy.
**
Resected prior or during CRLM resection